Literature DB >> 23124154

An ocular form of myasthenia gravis with a high titer of anti-MuSK antibodies during a long-term follow-up.

Ai Hosaka1, Hiroshi Takuma, Kiyoe Ohta, Akira Tamaoka.   

Abstract

We herein report a case of ocular myasthenia gravis (MG) that was highly positive for anti-muscle-specific tyrosine kinase (MuSK) antibodies. The examined patient exhibited bilateral ptosis and lateral gaze palsy without any generalized symptoms and was diagnosed with ocular MG with anti-MuSK antibodies. She responded to treatment with prednisolone and immunosuppressants and experienced only ocular symptoms for four years and eight months after onset. Ocular MG with anti-MuSK antibodies lasting for a long term has rarely been described. Our findings suggest that it may be reasonable to test for the presence of anti-MuSK antibodies in patients who present with external ophthalmoplegia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124154     DOI: 10.2169/internalmedicine.51.8196

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

Review 1.  Anti-MuSK ocular myasthenia with extrinsic ocular muscle atrophy: a new clinical phenotype?

Authors:  Dario Ricciardi; Vincenzo Todisco; Gioacchino Tedeschi; Giovanni Cirillo
Journal:  Neurol Sci       Date:  2019-08-17       Impact factor: 3.307

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

3.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

Review 4.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.